Optic Neuropathy Therapeutics Clinical Trials Market H1 2015 Research Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Optic Neuropathy Global Clinical Trials Review, H1, 2015” report to its store. The report provides data on the Optic Neuropathy clinical trial scenario.

Optic Neuropathy Global Clinical Trials Review

Optic Neuropathy Global Clinical Trials Review

Optic neuropathy affects more women than men and it generally occurs in adults of more than 40 years old.

The clinical trial report “Optic Neuropathy Global Clinical Trials Review, H1, 2015″ provides elemental information and data relating to the clinical trials on Optic Neuropathy. Optic neuropathy is a common cause of vision loss. Demyelinating optic neuritis is another term for this eye condition. The optic nerve contains approximately 1.2 million nerve fibers. The clinical signs of optic neuropathy are visual field defect, dyschromatopsia and abnormal papillary response. Ischemic optic neuropathy is damage of the optic nerve caused by a blockage of its blood supply. There are two different mechanisms responsible for vision loss first one is arteritic and second form is non-arteritic.

Optic neuropathy affects more women than men and it generally occurs in adults of more than 40 years old. Other causes of optic neuropathy include infections, optical herpes, other viral infections, sinusitis, neurological disorders, leber hereditary optic neuropathy, nutritional deficiency and toxins, including alcohol and tobacco.. Treatment of optic neuritis has changed in recent years. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Optic Neuropathy.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

The report also includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Companies discussed in this optic neuropathy therapeutics clinical trials report include Sigma-Tau S.p.A., SBI Biotech Co., Ltd., Regenera Pharma Ltd., Highmark Inc., Eli Lilly and Company, Bayer AG, Allergan, Inc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=268943 . (This is a premium report priced at US$2500 for a single user License.)

The report also includes the clinical trial overview of top institutes / government that includes Tehran University of Medical Sciences, Shahid Beheshti University of Medical Sciences, Hong Kong Eye Hospital, Second Military Medical University, Jikei University School of Medicine, Isfahan University of Medical Sciences, Mount Sinai Hospital, University of Colorado, University Hospital Tubingen and National Eye Institute.

Explore more reports on Clinical Trial industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/clinical-trial .

More reports on Clinical Trials:

Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015
This report provides elemental information and data relating to the clinical trials on Post Operative Nausea And Vomiting. Companies discussed in this post operative nausea and vomiting clinical trials report include Merck & Co., Inc., GlaxoSmithKline plc, Acacia Pharma Ltd., Helsinn Holding S.A., GW Pharmaceuticals plc, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Accenture Plc.

Clinical trial overview of top institutes or government includes Yonsei University, Tabriz University of Medical Sciences, Seoul National University Hospital, Tehran University of Medical Sciences, Isfahan University of Medical Sciences, Tokushima University Hospital, Hvidovre University Hospital, Bispebjerg Hospital, Arak University of Medical Sciences, King Edward Memorial Hospital. Complete report details @ http://www.rnrmarketresearch.com/post-operative-nausea-and-vomiting-global-clinical-trials-review-h1-2015-market-report.html .

Macular Edema Global Clinical Trials Review, H1, 2015
The report provides data on the Macular Edema clinical trial scenario. Companies and Institutes discussed in this report includes Allergan, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Eyetech Pharmaceuticals, Inc., Bayer AG, Clearside BioMedical, Inc., National Eye Institute, Johns Hopkins University, Shahid Beheshti University of Medical Sciences, Assistance Publique - Hopitaux de Paris, Queen's University, Kagoshima University, Wills Eye Institute, Yamagata University Hospital, University of California, San Francisco, Johann Wolfgang Goethe University Hospitals. Complete report details @ http://www.rnrmarketresearch.com/macular-edema-global-clinical-trials-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website